Dong-A signs out-licensing agreement for novel DPP-IV inhibitor with Alkem India

Published: 2012-12-26 06:57:00

Updated: 2012-12-26 06:57:00

Dong-A Pharm announced Friday that it has signed an out-licensing agreement for Dong-A’s novel and selective DPP-IV (dipeptidyl peptidase) inhibitor, DA-1229, with Alkem Laboratories, one of the largest pharmaceutical firms in India.

Under the deal, Dong-A authorized that Alkem would have the ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK